A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

NCT02807454 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

37

Enrollment

INDUSTRY

Sponsor class

Stopped Health Authority request due to class effect

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Durvalumab
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Celgene